pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

851 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • <![CDATA[MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT ]]>
    <![CDATA[R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies like pimicotinib in TGCT enables a tumor biology–informed approach to care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma]]>
    <![CDATA[Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer]]>
    <![CDATA[Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.]]>
← prev
page 29 of 35
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • Amgen, AbbVie say IRA negotiations impacted Q1 sales
    At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in th…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC]]>
    <![CDATA[Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma]]>
    <![CDATA[Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.]]>
    onclive · 2mo ago↗ source
  • Lilly plans new $4.5B manufacturing investment in Indiana
    Eli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana as drugmakers pledge more US projects. The world’s largest pharma company, headquart…
    Endpoints · 2mo ago↗ source
  • BeOne culls five cancer programs and an autoimmune Phase 2
    BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experi…
    Endpoints · 2mo ago↗ source
  • Lonza looks to ride ADC wave with upcoming factory, workforce expansion
    BASEL, Switzerland — Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next year and plans to increase its headcount.…
    Endpoints · 2mo ago↗ source
  • <![CDATA[FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC]]>
    <![CDATA[An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma]]>
    <![CDATA[Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Sznol on Biomarkers of Response in Metastatic Melanoma]]>
    <![CDATA[Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery]]>
    <![CDATA[The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.]]>
    onclive · 2mo ago↗ source
  • Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts
    🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, accord…
    Endpoints · 2mo ago↗ source
  • Former Orbital scientists launch new mRNA therapy startup
    Two scientists think they've solved a technical problem that has kept the mRNA revolution from reaching its full potential. Now, they're launching ParcelBio with $13 million in seed funding to dev…
    Endpoints · 2mo ago↗ source
  • Avalo scores Phase 2 success in comeback bid, raises $375M
    Avalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an exper…
    Endpoints · 2mo ago↗ source
  • <![CDATA[ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go]]>
    <![CDATA[Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>
    onclive · 2mo ago↗ source
  • GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane
    GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suz…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management]]>
    <![CDATA[Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration]]>
    <![CDATA[New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Disease Assessment and Mutational Testing in Progressive CLL]]>
    <![CDATA[Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Clinical Scenario Presentation and Treatment Approach for Progressive Disease]]>
    <![CDATA[Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC]]>
    <![CDATA[Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026]]>
    <![CDATA[SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.]]>
    onclive · 2mo ago↗ source